Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites. Date range. Start Date. End Date. Corporate Vaccines Medicines Sustainability Consumer healthcare Research and …
Press releases | GSK US
WEBGSK’s THRIVE@50+ campaign with Brooke Shields encourages people aged 50 and over to discuss shingles risk and vaccination with their doctor. Download (PDF, 207.8KB) September 11 2024.
GlaxoSmithKline News | GSK News - NewsNow
WEBGlaxoSmithKline News. NewsNow aims to be the world's most accurate and comprehensive aggregator of GlaxoSmithKline news, covering the latest share price, company announcements, vaccine trials, product news and more from the best online publications. Every story from every site is brought to you automatically and continuously 24/7, within around ...
GSK delivers continued strong performance and upgrades 2024 …
WEBJul 31, 2024 · Trelegy £0.8 billion +41%. Total operating profit -22% and Total EPS -27% for Q2 2024 primarily reflected higher charges for CCL (1) remeasurements driven by improved longer term HIV prospects and foreign currency movements. Core operating profit +18% (with further positive impact of 3% ex COVID) and …
GSK makes a strong start to 2024 with improving outlook for the …
WEBMay 1, 2024 · 2024 guidance updated and dividends: Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%) Dividend declared of 15p for Q1 2024; 60p expected for Full Year 2024.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · Tony Wood, Chief Scientific Officer, GSK, said: “Today marks a turning point in our effort to reduce the significant burden of RSV. AREXVY is the first approved RSV vaccine for older adults, expanding GSK’s industry-leading vaccine portfolio, which protects millions of people from infectious diseases each year.
GSK raises profit outlook on strong vaccine, HIV drug sales
WEBMay 1 (Reuters) - GSK (GSK.L) raised its full-year profit forecast on Wednesday on strong demand for its common respiratory vaccine and specialty HIV medicines, though it expects sales growth to ...
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US ... - GSK
WEBJul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR ...
GlaxoSmithKline (GSK) Gains FDA Clearance for First HIV Prevention ...
WEBDec 21, 2021 · GlaxoSmithKline Plcreceived U.S. clearance for the first long-acting injection for the prevention of HIV, a significant development for the company as it prepares to split in two next year. The U ...
GSK completes acquisition of Aiolos Bio for up to $1.4 bln
WEBFeb 15, 2024 · GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. ... Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching ...
- Some results have been removed